Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) shares fell 24.7% during mid-day trading on Monday . The stock traded as low as $1.13 and last traded at $1.13. 2,300 shares traded hands during trading, an increase of 82% from the average session volume of 1,267 shares. The stock had previously closed at $1.50.
Silence Therapeutics Price Performance
The stock has a 50 day simple moving average of $1.48 and a 200 day simple moving average of $3.29.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Read More
- Five stocks we like better than Silence Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- 5 Top Rated Dividend Stocks to Consider
- The 3 Most Talked About Investments on WallStreetBets Right Now
- The Most Important Warren Buffett Stock for Investors: His Own
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
